Temporal trends in overall survival of metastatic lung cancer patients of Institut Curie, 2000-2020

With the introduction of targeted therapy in 2010 and immunotherapy in 2018, overall survival of metastatic lung cancer patients in clinical studies improved. Whether these improvements translate into the clinical setting is not yet clear. A retrospective study at Institut Curie (Paris, France) included all patients treated for metastatic lung cancer at the institute from 2000 to 2020. Among patients treated from 2000 to 2009, 2010 to 2017, and 2018 to 2020 the median overall survival was 11.1, 15.5, and 16.2 months, respectively. Among metastatic non-small cell lung cancer patients the median overall survival in these three periods was 11.2, 17.2, and 18.2 months, respectively, while among patients with metastatic small cell lung cancer it was 10.9, 11.7, and 11.2 months, respectively. Outcomes were better for women as compared with men in all periods. The authors conclude that among patients with metastatic non-small cell lung cancer overall survival improved coinciding with the introduction of targeted therapy in 2010 and of immunotherapy in 2018. This improvement was not seen among metastatisc small cell lung cancer patients.